Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2019

View Archived Issues

Soricimed provides update on its PDC program, including in vivo data for SBI-1301

OAT-1746, a novel arginase inhibitor, reduces tumor growth in murine glioma models

Allopregnanolone affects metabolic and lipid pathways in Alzheimer's disease

BARDA exercises option to support Qpex product development

BioMarin reports encouraging final phase III data for vosoritide in children with achondroplasia

FDA removes partial clinical hold for multiple-ascending-dose study of RGLS-4326

Health Canada approves Erleada for the treatment of mCSPC

First patient enrolled in pivotal phase III InnovAATe study of Kamada's inhaled AAT

Sanofi presents data from phase I repeat-dosing study of BIVV-001

Pharmacokinetic and antidrug antibody status of ABP-959 biosimilar compared to eculizumab

Phase Ib results for PVX-410 vaccine in combination with durvalumab in TNBC

SM-08502 demonstrates promising activity in TNBC models

Macrophage activity backfires in S. aureus infection

Phase III GEMINI study of AXS-05 in MDD achieves primary endpoint

BeiGene presents cohort 1 results of ASPEN study of zanubrutinib in Waldenstrom's macroglobulinemia

Amgen discloses new KRAS G12C inhibitors

TAM receptor family tyrosine kinase inhibitors patented by Rigel Pharmaceuticals

VenatoRx Pharmaceuticals identifies new carbapenems

Merck & Co. presents new IDO-1 inhibitors

New HIV integrase inhibitors identified at Shionogi

[18F]GTP-1 imaging shown to be useful to detect cognitive decline

Study shows causal link between elevated activity of type 1 interferon and human disease

Tonix to advance development of TNX-601 CR for depression and PTSD

Medivir ends phase II colorectal cancer study of birinapant with pembrolizumab for futility

FDA approves Xtandi for metastatic castration-sensitive prostate cancer

Antisense Therapeutics plans to advance ATL-1102 into phase IIb for DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...